Unjoni Ewropea - Malti - EMA (European Medicines Agency)

axunio pharma gmbh - pirfenidone - fibrożi pulmonari idjopatika - immunosoppressanti - pirfenidone aet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

viatris limited - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - immunosoppressanti - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

roche registration gmbh - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - immunosoppressanti - esbriet is indicated in adults for the treatment of idiopathic pulmonary fibrosis.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - nintedanib - fibrożi pulmonari idjopatika - aġenti antineoplastiċi - ofev huwa indikat fl-adulti għat-trattament tal-fibrożi pulmonari idjopatika (ipf).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig - ritlecitinib tosilate - alopecia areata - immunosoppressanti - litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

laboratorios farmacéuticos rovi, s.a. - risperidone - skizofrenija - psikolettiċi - treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international n.v. - palmpalidone palmitate - skizofrenija - psikolettiċi - xeplion huwa indikat għal trattament ta 'manteniment ta' skiżofrenja f'pazjenti adulti stabilizzati b'paliperidone jew risperidone. in selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, xeplion may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international n.v. - abiraterone acetate - neoplasmi prostatiċi - terapija endokrinali - zytiga huwa indikat ma 'prednisone jew prednisolone: - trattament tal-kanċer metastatiku tal-kastrazzjoni reżistenti għall-kanċer tal-prostata fl-irġiel adulti li huma asintomatiċi jew ħafif sintomatika wara l-falliment tat-terapija tal-privazzjoni tal-androgen fil-għalihom kimoterapija għadu mhux klinikament indicatedthe-trattament tal-kanċer metastatiku tal-kastrazzjoni reżistenti għall-kanċer tal-prostata fl-irġiel adulti li l-marda tagħhom mexa fuq jew wara docetaxel kimoterapija bbażata fuq il-kors ta'.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

accord healthcare s.l.u. - abiraterone acetate - neoplasmi prostatiċi - terapija endokrinali - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

krka, d.d., novo mesto - abiraterone acetate - neoplasmi prostatiċi - terapija endokrinali - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.